cWith 130 years of experience in pharmaceuticals and more than 58 million patients around the world, AbbVie, a spin-off of Abbott, is one of the most relevant companies in its sector. Led by María José Sánchez, the first woman to hold the general management of the company, aims to continue being a bridge between doctors and the more than 1.6 million patients it has.
How many years has AbbVie been operating in Colombia?
AbbVie is a company that comes from a spin-off from Abbott, which is a company that is more than 130 years old. It began its operation 10 years ago, more or less the same time it began in Colombia. It is a relatively young company, but it is a biopharmaceutical company that operates in four lines of business, that is, it covers four diseases: hematology, immunology, neurosciences and visual health.
What is the company’s strongest line of business in the Colombian market?
We participate equally in the four therapeutic areas. This is proportional to the population we serve, which is close to 1.6 million people in Colombia with innovative therapies. If we made a comparison, it would be close to the population of Barranquilla.
Where does AbbVie rank in terms of sales?
In terms of sales, AbbVie is in the top 3 in the world and reaches more or less 58 million patients. In Colombia we have sales around US$100 millionso it is more or less 60% of the total cluster.
What types of innovative therapies do you have?
In the case of immunology we have three specific molecules, but for confidentiality reasons we cannot reveal the names. In the case of neurosciences we have some such as Botox, for hemato-oncology we have others. In each of the business lines we participate in 11 types of diseases such as arthritis, leukemias and lymphomas. In the case of visual health participation we are with glaucoma and everything related to the retina.
Who are your main clients?
In the end, with whom we operate and relate are both the EPS and the logistics operators with whom we carry out negotiations.. Regardless of who we participate with, in the end it is the doctors who make the decision about the therapies to reach the patients, because in the end the greatest purpose here is always always them.
